T. Rowe Price Associates’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15,601
| Closed | -$26K | – | 3098 |
|
|
2025
Q1 | $26K | Buy |
+15,601
| New | +$31.3K | ﹤0.01% | 2990 |
|
|
2024
Q4 | – | Sell |
-20,652
| Closed | -$120K | – | 3033 |
|
|
2024
Q3 | $120K | Hold |
20,652
| – | – | ﹤0.01% | 2785 |
|
|
2024
Q2 | $167K | Buy |
20,652
+8,153
| +65% | +$85.8K | ﹤0.01% | 2631 |
|
|
2024
Q1 | $174K | Sell |
12,499
-1
| -0% | -$9 | ﹤0.01% | 2661 |
|
|
2023
Q4 | $77K | Hold |
12,500
| – | – | ﹤0.01% | 2752 |
|
|
2023
Q3 | $59K | Buy |
12,500
+5,708
| +84% | +$31.5K | ﹤0.01% | 2755 |
|
|
2023
Q2 | $37K | Sell |
6,792
-3,722
| -35% | -$30K | ﹤0.01% | 2833 |
|
|
2023
Q1 | $104K | Buy |
10,514
+2,547
| +32% | +$43.4K | ﹤0.01% | 2681 |
|
|
2022
Q4 | $149K | Sell |
7,967
-1,989
| -20% | -$45.1K | ﹤0.01% | 2620 |
|
|
2022
Q3 | $207K | Sell |
9,956
-751
| -7% | -$19.2K | ﹤0.01% | 2531 |
|
|
2022
Q2 | $222K | Buy |
10,707
+240
| +2% | +$6.76K | ﹤0.01% | 2559 |
|
|
2022
Q1 | $451K | Buy |
10,467
+880
| +9% | +$39.6K | ﹤0.01% | 2384 |
|
|
2021
Q4 | $574K | Sell |
9,587
-4,062
| -30% | -$325K | ﹤0.01% | 2319 |
|
|
2021
Q3 | $1.17M | Buy |
13,649
+708
| +5% | +$71K | ﹤0.01% | 1973 |
|
|
2021
Q2 | $1.44M | Buy |
12,941
+790
| +7% | +$75.9K | ﹤0.01% | 1892 |
|
|
2021
Q1 | $1.35M | Sell |
12,151
-931
| -7% | -$122K | ﹤0.01% | 1897 |
|
|
2020
Q4 | $1.39M | Buy |
13,082
+6,026
| +85% | +$802K | ﹤0.01% | 1789 |
|
|
2020
Q3 | $982K | Buy |
7,056
+1,833
| +35% | +$382K | ﹤0.01% | 1799 |
|
|
2020
Q2 | $1.69M | Buy |
5,223
+1,776
| +52% | +$285K | ﹤0.01% | 1588 |
|
|
2020
Q1 | $308K | Buy |
3,447
+1,919
| +126% | +$118K | ﹤0.01% | 2182 |
|
|
2019
Q4 | $61K | Buy |
1,528
+308
| +25% | +$9.27K | ﹤0.01% | 2491 |
|
|
2019
Q3 | $30K | Buy |
1,220
+77
| +7% | +$2.34K | ﹤0.01% | 2502 |
|
|
2019
Q2 | $40K | Hold |
1,143
| – | – | ﹤0.01% | 2523 |
|
|
2019
Q1 | $51K | Buy |
1,143
+9
| +0.8% | +$454 | ﹤0.01% | 2503 |
|
|
2018
Q4 | $54K | Buy |
1,134
+13
| +1% | +$790 | ﹤0.01% | 2517 |
|
|
2018
Q3 | $75K | Buy |
1,121
+42
| +4% | +$2.34K | ﹤0.01% | 2548 |
|
|
2018
Q2 | $51K | Buy |
1,079
+7
| +0.7% | +$386 | ﹤0.01% | 2564 |
|
|
2018
Q1 | $61K | Buy |
1,072
+222
| +26% | +$12K | ﹤0.01% | 2526 |
|
|
2017
Q4 | $42K | Hold |
850
| – | – | ﹤0.01% | 2549 |
|
|
2017
Q3 | $65K | Hold |
850
| – | – | ﹤0.01% | 2534 |
|
|
2017
Q2 | $80K | Hold |
850
| – | – | ﹤0.01% | 2502 |
|
|
2017
Q1 | $68K | Buy |
+850
| New | +$67.7K | ﹤0.01% | 2522 |
|
Other funds holding INO
DTC
T. Rowe Price Associates's INO Position: Q2 2025 in Review
T. Rowe Price Associates sold out of Inovio Pharmaceuticals (INO) in Q2 2025, closing a stake of 15,601 shares — an estimated $26K sold.
T. Rowe Price Associates first reported a position in INO in Q1 2017 and held it in 32 quarters. The position peaked at $1.69M in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2025.
- T. Rowe Price Associates reported no remaining Inovio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- T. Rowe Price Associates sold 15,601 Inovio Pharmaceuticals shares in Q2 2025, an estimated $26K.
- T. Rowe Price Associates first reported a position in Inovio Pharmaceuticals in Q1 2017 and held it in 32 quarters.
- T. Rowe Price Associates's Inovio Pharmaceuticals position peaked at $1.69M in Q2 2020.
- 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2025.
Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.